trastuzumab emtansine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
humanized origin 4990 1018448-65-1

Description:

MoleculeDescription

Synonyms:

  • trastuzumab-DM1 conjugate
  • trastuzumab emtansine
  • ado-trastuzumab emtansine
  • kadcyla
  • PRO132365
  • trastuzumab-MCC-DM1
  • T-DM1
  • huN901-DM1
Immunotoxin that consists of humanized monoclonal anti-HER2 antibody TRASTUZUMAB covalently linked to anti-microtubule agent MAYTANSINOID DM1 for treatment of metastatic breast cancer in patients who previously received trastuzumab and a TAXANES, separately or in combination.
  • Molecular weight:
  • Formula: (C47H62ClN4O14S)3-4
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
12 mg P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Sept. 20, 2013 PMDA Chugai Pharmaceutical Co., Ltd
Feb. 22, 2013 FDA GENENTECH
Nov. 15, 2013 EMA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Disease progression 1000.32 23.24 604 26149 156011 90445683
Metastases to central nervous system 892.15 23.24 292 26461 17250 90584444
Platelet count decreased 471.68 23.24 361 26392 136608 90465086
Thrombocytopenia 465.70 23.24 428 26325 208297 90393397
Myelosuppression 394.31 23.24 227 26526 53364 90548330
Ejection fraction decreased 363.23 23.24 170 26583 26083 90575611
Neuropathy peripheral 357.12 23.24 307 26446 136663 90465031
Metastases to lymph nodes 323.86 23.24 124 26629 11565 90590129
Metastases to lung 276.48 23.24 121 26632 15870 90585824
Epistaxis 255.25 23.24 207 26546 84918 90516776
Palmar-plantar erythrodysaesthesia syndrome 222.95 23.24 125 26628 27898 90573796
Nodular regenerative hyperplasia 204.02 23.24 46 26707 637 90601057
Metastases to bone 198.11 23.24 112 26641 25393 90576301
Portal hypertension 190.36 23.24 66 26687 4635 90597059
Malignant neoplasm progression 176.01 23.24 186 26567 106684 90495010
Metastases to skin 151.92 23.24 46 26707 2094 90599600
Cardiotoxicity 136.91 23.24 67 26686 11322 90590372
Radiation necrosis 135.94 23.24 33 26720 640 90601054
Vascular device infection 133.85 23.24 67 26686 11885 90589809
Breast cancer metastatic 132.71 23.24 72 26681 15060 90586634
Neoplasm progression 130.76 23.24 107 26646 44379 90557315
Polyneuropathy 126.54 23.24 76 26677 19265 90582429
Metastases to liver 121.61 23.24 86 26667 28721 90572973
Skin fissures 121.41 23.24 76 26677 20733 90580961
Joint swelling 120.56 23.24 7 26746 503293 90098401
Aspartate aminotransferase increased 120.15 23.24 150 26603 102787 90498907
Hepatopulmonary syndrome 116.53 23.24 21 26732 81 90601613
Metastasis 111.15 23.24 48 26705 6089 90595605
Pneumonitis 106.83 23.24 95 26658 44075 90557619
Spider naevus 104.75 23.24 21 26732 158 90601536
Alanine aminotransferase increased 103.76 23.24 150 26603 118188 90483506
Breast cancer recurrent 102.82 23.24 44 26709 5459 90596235
Hepatotoxicity 101.85 23.24 94 26659 45748 90555946
Recurrent cancer 101.40 23.24 35 26718 2424 90599270
Pleural effusion 101.19 23.24 144 26609 111847 90489847
Drug hypersensitivity 98.42 23.24 11 26742 463598 90138096
Brain oedema 97.68 23.24 62 26691 17323 90584371
Rheumatoid arthritis 93.52 23.24 3 26750 362611 90239083
Blood lactate dehydrogenase increased 92.65 23.24 70 26683 25862 90575832
Left ventricular dysfunction 89.17 23.24 55 26698 14614 90587080
Systemic lupus erythematosus 86.72 23.24 5 26748 361891 90239803
Blood bilirubin increased 84.88 23.24 83 26670 43387 90558307
Abdominal discomfort 84.11 23.24 19 26734 477309 90124385
Streptococcal sepsis 81.60 23.24 33 26720 3551 90598143
Diarrhoea 80.99 23.24 513 26240 938677 89663017
Nail bed inflammation 79.59 23.24 27 26726 1774 90599920
Arthropathy 79.47 23.24 8 26745 366234 90235460
Breast disorder 78.94 23.24 30 26723 2737 90598957
Nasal mucosal disorder 78.78 23.24 27 26726 1830 90599864
Interstitial lung disease 77.64 23.24 104 26649 76301 90525393
Gamma-glutamyltransferase increased 76.98 23.24 74 26679 37878 90563816
Pseudomonal sepsis 75.79 23.24 33 26720 4269 90597425
Excessive eye blinking 74.38 23.24 24 26729 1348 90600346
Blood alkaline phosphatase increased 74.36 23.24 81 26672 47998 90553696
Paronychia 72.73 23.24 39 26714 7967 90593727
Condition aggravated 72.58 23.24 43 26710 595502 90006192
Blood uric acid decreased 72.16 23.24 21 26732 832 90600862
Neutropenia 71.24 23.24 185 26568 224719 90376975
Breast neoplasm 71.06 23.24 24 26729 1556 90600138
Treatment failure 70.42 23.24 5 26748 303923 90297771
Product dose omission issue 69.95 23.24 4 26749 291683 90310011
Swelling 69.31 23.24 19 26734 419039 90182655
Non-cirrhotic portal hypertension 68.47 23.24 17 26736 363 90601331
Nausea 67.67 23.24 558 26195 1109758 89491936
Pericarditis 67.02 23.24 3 26750 270148 90331546
Metastases to spine 66.88 23.24 29 26724 3714 90597980
Hypokalaemia 66.37 23.24 130 26623 130986 90470708
Axillary pain 65.62 23.24 25 26728 2296 90599398
Eosinophil percentage increased 64.35 23.24 20 26733 994 90600700
Radiation pneumonitis 63.49 23.24 23 26730 1835 90599859
Tumour marker increased 63.39 23.24 32 26721 5775 90595919
Constipation 63.06 23.24 204 26549 280191 90321503
Mucosal inflammation 62.50 23.24 81 26672 57544 90544150
Gingival bleeding 61.75 23.24 44 26709 14859 90586835
Ascites 59.59 23.24 72 26681 47668 90554026
Hyperchlorhydria 58.84 23.24 22 26731 1919 90599775
Telangiectasia 58.25 23.24 20 26733 1363 90600331
Hepatic function abnormal 58.09 23.24 70 26683 46218 90555476
Hemianopia 57.34 23.24 22 26731 2060 90599634
Peripheral sensory neuropathy 57.03 23.24 35 26718 9215 90592479
Anaemia 56.67 23.24 230 26523 352572 90249122
Haematotoxicity 56.58 23.24 39 26714 12496 90589198
Sinusitis 55.89 23.24 16 26737 343072 90258622
Wound 55.50 23.24 11 26742 302969 90298725
Musculoskeletal stiffness 53.83 23.24 11 26742 296521 90305173
Impaired healing 53.82 23.24 4 26749 234195 90367499
Hand dermatitis 51.97 23.24 15 26738 577 90601117
Lymphangiosis carcinomatosa 50.86 23.24 19 26734 1653 90600041
Discomfort 50.16 23.24 10 26743 274325 90327369
Blood creatinine decreased 48.93 23.24 28 26725 6487 90595207
Drug interaction 48.66 23.24 11 26742 276442 90325252
Hyperbilirubinaemia 48.41 23.24 37 26716 13899 90587795
Maternal exposure during pregnancy 48.21 23.24 23 26730 360040 90241654
Performance status decreased 47.93 23.24 24 26729 4256 90597438
Death 47.92 23.24 263 26490 456288 90145406
Microvascular coronary artery disease 47.57 23.24 12 26741 274 90601420
Dyschezia 47.31 23.24 21 26732 2844 90598850
Wheezing 47.21 23.24 7 26746 238073 90363621
Candida infection 46.87 23.24 54 26699 34003 90567691
Radiation skin injury 46.69 23.24 16 26737 1084 90600610
Lymphoedema 46.65 23.24 36 26717 13717 90587977
Vessel puncture site bruise 46.55 23.24 13 26740 443 90601251
Asthma 46.04 23.24 8 26745 242152 90359542
Product use in unapproved indication 45.75 23.24 21 26732 336215 90265479
Therapeutic product effect decreased 45.09 23.24 13 26740 277558 90324136
Urticaria 44.99 23.24 18 26735 312716 90288978
Electric shock sensation 44.71 23.24 17 26736 1553 90600141
Transaminases increased 44.64 23.24 55 26698 37137 90564557
Splenomegaly 44.20 23.24 34 26719 12890 90588804
Nail dystrophy 43.86 23.24 16 26737 1302 90600392
Asthenopia 43.79 23.24 20 26733 2894 90598800
Varicose vein 43.33 23.24 27 26726 7300 90594394
Ejection fraction 43.17 23.24 20 26733 2991 90598703
Mobility decreased 42.12 23.24 11 26742 250723 90350971
Carcinoembryonic antigen increased 41.31 23.24 18 26735 2332 90599362
Arteriovenous malformation 41.28 23.24 16 26737 1539 90600155
Drug intolerance 41.01 23.24 43 26710 447548 90154146
Febrile neutropenia 40.93 23.24 121 26632 158228 90443466
Lacrimation increased 40.80 23.24 45 26708 27017 90574677
Metastases to pleura 40.36 23.24 17 26736 2027 90599667
Therapeutic product effect incomplete 40.10 23.24 5 26748 193891 90407803
Lymphadenopathy 40.05 23.24 58 26695 45717 90555977
Intracranial pressure increased 40.03 23.24 25 26728 6786 90594908
Dry skin 39.41 23.24 83 26670 87990 90513704
Gastrointestinal toxicity 39.33 23.24 28 26725 9439 90592255
Confusional state 38.99 23.24 34 26719 386171 90215523
Seizure 38.85 23.24 116 26637 152513 90449181
Varices oesophageal 38.85 23.24 20 26733 3759 90597935
Tumour pain 38.29 23.24 16 26737 1871 90599823
Hypertransaminasaemia 38.17 23.24 34 26719 15791 90585903
Skin toxicity 37.63 23.24 24 26729 6755 90594939
Pituitary tumour 37.44 23.24 13 26740 916 90600778
Cellulitis 36.23 23.24 82 26671 91255 90510439
Metastases to meninges 36.20 23.24 19 26734 3716 90597978
Folate deficiency 36.19 23.24 18 26735 3147 90598547
Injection site extravasation 35.92 23.24 26 26727 8993 90592701
Vulvovaginal candidiasis 35.43 23.24 19 26734 3881 90597813
Neutrophil count decreased 35.05 23.24 70 26683 71462 90530232
Hydrocephalus 34.89 23.24 22 26731 6072 90595622
Vulvovaginal pain 34.60 23.24 18 26735 3456 90598238
Sleep disorder 34.59 23.24 8 26745 198022 90403672
Eastern Cooperative Oncology Group performance status worsened 34.57 23.24 15 26738 1924 90599770
Cardiac dysfunction 34.01 23.24 18 26735 3579 90598115
Hiccups 33.98 23.24 17 26736 3009 90598685
Hepatic cirrhosis 33.55 23.24 64 26689 63189 90538505
Tumour haemorrhage 33.46 23.24 15 26738 2079 90599615
Inappropriate schedule of product administration 33.22 23.24 3 26750 149930 90451764
Venoocclusive liver disease 32.73 23.24 21 26732 5972 90595722
Anal erythema 32.65 23.24 9 26744 292 90601402
Osteoarthritis 32.09 23.24 9 26744 195721 90405973
Neoplasm 31.72 23.24 24 26729 8879 90592815
Bone marrow infiltration 30.94 23.24 11 26742 831 90600863
Depression 30.89 23.24 26 26727 300575 90301119
Bone pain 30.78 23.24 61 26692 61922 90539772
Injury 30.68 23.24 10 26743 197339 90404355
Nail infection 30.52 23.24 15 26738 2557 90599137
Central nervous system infection 30.45 23.24 11 26742 870 90600824
Type 2 diabetes mellitus 30.38 23.24 11 26742 203233 90398461
Mucosal dryness 30.38 23.24 16 26737 3151 90598543
Hyperaesthesia 29.88 23.24 25 26728 10677 90591017
Fall 29.71 23.24 61 26692 481749 90119945
Nail bed bleeding 29.54 23.24 9 26744 418 90601276
Myalgia 29.53 23.24 116 26637 175009 90426685
Biliary sepsis 29.25 23.24 11 26742 975 90600719
Device related infection 29.13 23.24 37 26716 25749 90575945
Pulmonary mass 28.96 23.24 39 26714 28733 90572961
Drug ineffective 28.39 23.24 267 26486 1384031 89217663
Metastases to soft tissue 28.04 23.24 8 26745 295 90601399
Hormone receptor positive breast cancer 27.93 23.24 10 26743 771 90600923
Neurotoxicity 27.80 23.24 33 26720 21434 90580260
Cough 27.63 23.24 195 26558 368767 90232927
Gait inability 27.47 23.24 5 26748 146451 90455243
Hepatic failure 27.26 23.24 45 26708 39683 90562011
Dysmenorrhoea 27.08 23.24 17 26736 4655 90597039
Pain 26.98 23.24 178 26575 996163 89605531
Arthritis 26.86 23.24 8 26745 167307 90434387
Hypersensitivity 26.83 23.24 59 26694 454618 90147076
Poor peripheral circulation 26.80 23.24 16 26737 4009 90597685
Water intoxication 26.67 23.24 9 26744 582 90601112
Weight increased 26.54 23.24 52 26701 417875 90183819
Breast pain 26.36 23.24 23 26730 10395 90591299
Hypothalamo-pituitary disorder 26.32 23.24 13 26740 2239 90599455
Nail bed tenderness 26.29 23.24 8 26745 370 90601324
Paravenous drug administration 26.28 23.24 4 26749 3 90601691
Axillary vein thrombosis 26.05 23.24 8 26745 382 90601312
Lymphocyte count decreased 25.82 23.24 41 26712 35009 90566685
Extravasation 25.70 23.24 14 26739 2950 90598744
Left ventricular dilatation 25.63 23.24 9 26744 656 90601038
Gastric varices 25.58 23.24 7 26746 221 90601473
Dental fistula 25.47 23.24 9 26744 668 90601026
Pleural neoplasm 25.26 23.24 8 26745 423 90601271
Bronchitis 25.12 23.24 7 26746 152920 90448774
Red cell distribution width increased 25.12 23.24 24 26729 12183 90589511
Conjunctivitis 25.07 23.24 35 26718 26671 90575023
Intracranial tumour haemorrhage 24.86 23.24 7 26746 246 90601448
Dermatitis acneiform 24.59 23.24 18 26735 6336 90595358
Skin mass 24.22 23.24 19 26734 7411 90594283
Adverse drug reaction 24.15 23.24 3 26750 116698 90484996
Subcapsular hepatic haematoma 24.12 23.24 4 26749 8 90601686
Hepatic lesion 24.08 23.24 17 26736 5656 90596038
Pneumothorax 24.06 23.24 29 26724 19138 90582556
Eosinophil count increased 23.72 23.24 24 26729 13057 90588637
Blood phosphorus decreased 23.51 23.24 16 26737 5018 90596676
Radical mastectomy 23.51 23.24 4 26749 10 90601684
Pneumonia 23.27 23.24 289 26464 637770 89963924
Scintillating scotoma 23.27 23.24 6 26747 150 90601544

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Paranasal sinus discomfort 54.89 45.41 10 537 1187 42619601
Therapy partial responder 46.46 45.41 15 532 20006 42600782

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Metastases to central nervous system 668.28 22.52 231 23185 22586 110543297
Disease progression 563.83 22.52 443 22973 243591 110322292
Myelosuppression 338.31 22.52 224 23192 94116 110471767
Platelet count decreased 309.73 22.52 308 23108 230135 110335748
Metastases to lymph nodes 297.39 22.52 114 23302 14918 110550965
Thrombocytopenia 274.69 22.52 353 23063 348532 110217351
Ejection fraction decreased 267.10 22.52 143 23273 40737 110525146
Neuropathy peripheral 265.86 22.52 253 23163 179024 110386859
Metastases to lung 210.04 22.52 101 23315 22962 110542921
Metastases to bone 180.72 22.52 101 23315 31271 110534612
Palmar-plantar erythrodysaesthesia syndrome 163.07 22.52 104 23312 40921 110524962
Epistaxis 161.62 22.52 167 23249 130205 110435678
Metastases to skin 145.74 22.52 42 23374 2257 110563626
Nodular regenerative hyperplasia 131.66 22.52 36 23380 1595 110564288
Radiation necrosis 128.67 22.52 31 23385 823 110565060
Vascular device infection 128.55 22.52 65 23351 16447 110549436
Breast cancer metastatic 126.76 22.52 57 23359 11124 110554759
Malignant neoplasm progression 125.22 22.52 169 23247 174398 110391485
Polyneuropathy 121.89 22.52 79 23337 31933 110533950
Portal hypertension 117.30 22.52 50 23366 8587 110557296
Skin fissures 109.79 22.52 67 23349 24391 110541492
Hepatopulmonary syndrome 102.04 22.52 20 23396 192 110565691
Neoplasm progression 95.26 22.52 91 23325 64504 110501379
Cardiotoxicity 93.54 22.52 53 23363 16828 110549055
Metastases to liver 91.77 22.52 69 23347 35317 110530566
Breast disorder 89.85 22.52 29 23387 2285 110563598
Nail bed inflammation 89.39 22.52 28 23388 2002 110563881
Nasal mucosal disorder 87.23 22.52 27 23389 1856 110564027
Aspartate aminotransferase increased 84.39 22.52 134 23282 159802 110406081
Nausea 84.07 22.52 496 22920 1235194 109330689
Left ventricular dysfunction 82.20 22.52 55 23361 23438 110542445
Streptococcal sepsis 81.13 22.52 33 23383 5039 110560844
Diarrhoea 79.14 22.52 460 22956 1139045 109426838
Hepatotoxicity 76.32 22.52 80 23336 63320 110502563
Spider naevus 76.25 22.52 15 23401 147 110565736
Blood lactate dehydrogenase increased 76.11 22.52 68 23348 44266 110521617
Alanine aminotransferase increased 74.56 22.52 137 23279 183636 110382247
Joint swelling 74.28 22.52 5 23411 442840 110123043
Paronychia 72.99 22.52 39 23377 11042 110554841
Pleural effusion 70.23 22.52 131 23285 177578 110388305
Drug interaction 70.19 22.52 11 23405 500172 110065711
Lymphoedema 69.84 22.52 42 23374 14887 110550996
Constipation 69.27 22.52 199 23217 357587 110208296
Recurrent cancer 67.82 22.52 26 23390 3397 110562486
Brain oedema 66.26 22.52 54 23362 31044 110534839
Metastasis 65.68 22.52 33 23383 8234 110557649
Gamma-glutamyltransferase increased 64.40 22.52 72 23344 61237 110504646
Axillary pain 63.53 22.52 23 23393 2563 110563320
Blood uric acid decreased 63.27 22.52 20 23396 1473 110564410
Pseudomonal sepsis 62.87 22.52 33 23383 9013 110556870
Excessive eye blinking 62.80 22.52 21 23395 1849 110564034
Drug hypersensitivity 61.46 22.52 11 23405 454079 110111804
Tumour marker increased 61.21 22.52 27 23389 5033 110560850
Blood alkaline phosphatase increased 60.71 22.52 75 23341 70860 110495023
Non-cirrhotic portal hypertension 58.16 22.52 16 23400 725 110565158
Eosinophil percentage increased 58.07 22.52 19 23397 1563 110564320
Hemianopia 57.59 22.52 22 23394 2846 110563037
Condition aggravated 57.57 22.52 43 23373 734793 109831090
Varicose vein 53.08 22.52 27 23389 6913 110558970
Hyperchlorhydria 52.20 22.52 19 23397 2150 110563733
Rheumatoid arthritis 51.36 22.52 3 23413 299610 110266273
Metastases to spine 50.46 22.52 24 23392 5319 110560564
Nail dystrophy 50.18 22.52 16 23400 1212 110564671
Product dose omission issue 50.16 22.52 5 23411 321777 110244106
Ejection fraction 49.93 22.52 20 23396 2935 110562948
Candida infection 49.77 22.52 56 23360 47953 110517930
Lymphangiosis carcinomatosa 49.70 22.52 19 23397 2463 110563420
Vessel puncture site bruise 49.09 22.52 13 23403 509 110565374
Hand dermatitis 48.85 22.52 14 23402 737 110565146
Pneumonitis 48.69 22.52 70 23346 76461 110489422
Asthenopia 48.60 22.52 20 23396 3144 110562739
Microvascular coronary artery disease 47.41 22.52 12 23404 392 110565491
Telangiectasia 47.25 22.52 17 23399 1860 110564023
Fatigue 46.59 22.52 426 22990 1215532 109350351
Blood creatinine decreased 46.12 22.52 27 23389 9110 110556773
Hypokalaemia 45.96 22.52 112 23304 182336 110383547
Radiation skin injury 45.71 22.52 16 23400 1616 110564267
Interstitial lung disease 45.69 22.52 95 23321 139239 110426644
Gingival bleeding 45.56 22.52 36 23380 19803 110546080
Radiation pneumonitis 44.75 22.52 21 23395 4515 110561368
Skin toxicity 44.65 22.52 29 23387 11754 110554129
Vulvovaginal candidiasis 44.55 22.52 19 23397 3266 110562617
Peripheral sensory neuropathy 44.30 22.52 33 23383 16647 110549236
Treatment failure 44.02 22.52 4 23412 277230 110288653
Blood bilirubin increased 41.91 22.52 65 23351 75907 110489976
Gastrointestinal toxicity 41.17 22.52 27 23389 11121 110554762
Performance status decreased 40.76 22.52 23 23393 7243 110558640
Carcinoembryonic antigen increased 40.51 22.52 17 23399 2807 110563076
Drug ineffective 40.13 22.52 176 23240 1520364 109045519
Product use in unapproved indication 39.28 22.52 23 23393 447354 110118529
Arthropathy 38.80 22.52 7 23409 287515 110278368
Breast cancer recurrent 38.54 22.52 18 23398 3828 110562055
Urticaria 38.49 22.52 10 23406 318847 110247036
Injection site extravasation 38.46 22.52 25 23391 10144 110555739
Mucosal inflammation 38.11 22.52 71 23345 96070 110469813
Pituitary tumour 37.86 22.52 13 23403 1240 110564643
Seizure 37.06 22.52 117 23299 221068 110344815
Systemic lupus erythematosus 37.02 22.52 5 23411 254333 110311550
Tumour pain 36.43 22.52 16 23400 2951 110562932
Abdominal discomfort 36.38 22.52 19 23397 393839 110172044
Bone pain 36.30 22.52 56 23360 65077 110500806
Electric shock sensation 35.79 22.52 14 23402 1930 110563953
Nail infection 35.77 22.52 15 23401 2473 110563410
Arteriovenous malformation 35.74 22.52 14 23402 1937 110563946
Urinary tract infection 35.52 22.52 150 23266 326132 110239751
Lacrimation increased 35.36 22.52 38 23378 30912 110534971
Pericarditis 35.22 22.52 3 23413 219111 110346772
Acute kidney injury 35.20 22.52 50 23366 635380 109930503
Metastases to pleura 34.98 22.52 14 23402 2049 110563834
Ascites 34.88 22.52 67 23349 92741 110473142
Bone marrow infiltration 34.20 22.52 11 23405 857 110565026
Hormone receptor positive breast cancer 34.17 22.52 10 23406 567 110565316
Toxicity to various agents 34.01 22.52 31 23385 480524 110085359
Asthma 33.97 22.52 6 23410 250285 110315598
Metastases to meninges 33.64 22.52 18 23398 5110 110560773
Vulvovaginal pain 33.63 22.52 15 23401 2869 110563014
Therapeutic product effect incomplete 33.54 22.52 4 23412 223801 110342082
Eastern Cooperative Oncology Group performance status worsened 33.22 22.52 15 23401 2954 110562929
Folate deficiency 33.17 22.52 17 23399 4421 110561462
Wheezing 32.78 22.52 7 23409 255223 110310660
Dry skin 32.51 22.52 71 23345 107582 110458301
Swelling 32.32 22.52 17 23399 351024 110214859
Hypertransaminasaemia 31.70 22.52 32 23384 24223 110541660
Haematotoxicity 31.63 22.52 30 23386 21052 110544831
Anaemia 31.56 22.52 211 23205 546875 110019008
Cough 30.30 22.52 184 23232 461457 110104426
Atrial fibrillation 30.11 22.52 6 23410 229636 110336247
Confusional state 30.00 22.52 33 23383 468647 110097236
Musculoskeletal stiffness 29.78 22.52 11 23405 279811 110286072
Dental fistula 29.56 22.52 9 23407 585 110565298
Cellulitis 29.24 22.52 75 23341 125941 110439942
Fall 29.15 22.52 52 23364 603430 109962453
Hyperbilirubinaemia 28.80 22.52 34 23382 30637 110535246
Nail bed tenderness 28.79 22.52 8 23408 376 110565507
Hydrocephalus 28.61 22.52 21 23395 10354 110555529
Poor peripheral circulation 28.28 22.52 15 23401 4182 110561701
Pleural neoplasm 28.20 22.52 8 23408 406 110565477
Pulmonary mass 28.06 22.52 37 23379 37264 110528619
Tumour haemorrhage 27.80 22.52 16 23400 5229 110560654
Conjunctivitis 27.74 22.52 35 23381 33757 110532126
Hypothalamo-pituitary disorder 27.54 22.52 13 23403 2833 110563050
Dysmenorrhoea 27.48 22.52 14 23402 3596 110562287
Nail discolouration 27.39 22.52 14 23402 3621 110562262
Discomfort 27.34 22.52 6 23410 214701 110351182
Breast pain 27.04 22.52 20 23396 9980 110555903
Central nervous system infection 26.78 22.52 11 23405 1721 110564162
Therapy partial responder 26.71 22.52 36 23380 37025 110528858
Drug intolerance 26.70 22.52 28 23388 406484 110159399
Nail bed bleeding 26.33 22.52 9 23407 847 110565036
Biliary sepsis 26.12 22.52 11 23405 1832 110564051
Tumour marker abnormal 25.96 22.52 7 23409 294 110565589
Transaminases increased 25.35 22.52 47 23369 63343 110502540
Therapeutic product effect decreased 25.33 22.52 10 23406 244306 110321577
Water intoxication 25.33 22.52 9 23407 950 110564933
Spinal pain 25.25 22.52 25 23391 18490 110547393
Lymphadenopathy 25.11 22.52 47 23369 63788 110502095
Sinusitis 24.98 22.52 16 23400 296672 110269211
Hepatic function abnormal 24.84 22.52 57 23359 89238 110476645
Breast neoplasm 24.47 22.52 9 23407 1049 110564834
Mobility decreased 24.16 22.52 10 23406 237412 110328471
Mean cell haemoglobin concentration decreased 24.05 22.52 15 23401 5667 110560216
Nasal dryness 24.00 22.52 15 23401 5691 110560192
Metastases to soft tissue 23.85 22.52 8 23408 711 110565172
Wound 23.65 22.52 10 23406 234427 110331456
Weight decreased 23.17 22.52 174 23242 467883 110098000
Back pain 23.15 22.52 146 23270 370850 110195033
Catheter site inflammation 23.08 22.52 9 23407 1231 110564652
Scintillating scotoma 22.96 22.52 6 23410 223 110565660
Skin mass 22.94 22.52 18 23398 9798 110556085
Splenomegaly 22.74 22.52 27 23389 24471 110541412

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FD03 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
MeSH PA D000074322 Antineoplastic Agents, Immunological
MeSH PA D000922 Immunotoxins
MeSH PA D000970 Antineoplastic Agents
MeSH PA D007155 Immunologic Factors
MeSH PA D050256 Antimitotic Agents
MeSH PA D050257 Tubulin Modulators
CHEBI has role CHEBI:35610 antineoplastic agent

Related Drugs by ATC class:

L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors 5 drugs
margetuximabpertuzumabtrastuzumabtrastuzumab deruxtecanzanidatamab-hrii

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
HER2-positive carcinoma of breast indication 427685000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Receptor tyrosine-protein kinase erbB-2 Kinase ANTIBODY BINDING DRUG LABEL DRUG LABEL
Tubulin beta Tumour-associated antigen INHIBITOR DRUG LABEL DRUG LABEL

External reference:

IDSource
SE2KH7T06F UNII
D09980 KEGG_DRUG
4032192 VUID
N0000186780 NUI
4032192 VANDF
C2935436 UMLSCUI
CHEBI:750159 CHEBI
CHEMBL1743082 ChEMBL_ID
DB05773 DRUGBANK_ID
CHEMBL1201585 ChEMBL_ID
9295 INN_ID
6928 IUPHAR_LIGAND_ID
1371041 RXNORM
199194 MMSL
29308 MMSL
d08069 MMSL
014910 NDDF
702836004 SNOMEDCT_US
896752005 SNOMEDCT_US
D000080044 MESH_DESCRIPTOR_UI
CHEMBL1743037 ChEMBL_ID
SE2KH7T06F INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
KADCYLA HUMAN PRESCRIPTION DRUG LABEL 1 50242-087 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS BLA 36 sections
KADCYLA HUMAN PRESCRIPTION DRUG LABEL 1 50242-088 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS BLA 36 sections